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Societal relevance
Cardiovascular disease (CVD) is the leading global cause of death, accounting for more 
than 17.3 million deaths per year, representing 1 of every 3 deaths [1]. This life-threatening 
disease is accompanied with enormous annual costs, reaching $863 billion in 2010 glob-
ally [2]. Almost half of the patients with newly diagnosed CVD have heart failure (HF). 
Importantly, HF is the only cardiovascular disease that has increased in prevalence over 
the last 20 years [3]. According to the American Heart Failure Association, the prevalence of 
HF will continue to increase with 46 % from 2012 to 2030, resulting in more than 8 million 
people with an age of 18 years or older with HF [4]. In the Netherlands, currently ~142.000 
patients suffer from HF, resulting in 940 million euros of annual costs for HF in 2011 in the 
Netherlands only [5]. In addition to the rising prevalence, the high five-year mortality of 
HF patients (52.6 %) did not decline since 2000, highlighting the ineffectiveness of current 
therapeutics and the urgent need to develop novel treatment strategies. Thus, improving 
HF therapy is necessary to prevent this disease to reach global epidemic proportions and 
to save the lives of millions of people around the world. However, to achieve this goal, we 
should expand the current knowledge concerning cellular processes driving HF develop-
ment, and identify molecular key players to test as potential therapeutic targets.
In this thesis, we identified multiple specific microRNA (miRNA) candidates with a 
pivotal regulatory function in cellular processes driving HF development. Identification of 
these miRNAs and interrogation of the mechanism underlying their function increases the 
understanding of HF development. Increased understanding of the processes driving HF 
progression expands the body of knowledge, benefitting the scientific community. More 
importantly, identified miRNA candidates can be probed for their safety and efficacy to 
impact cellular processes underlying HF development and to retard disease progression. 
In this thesis we identified several promising miRNA candidates that in a next stage should 
be tested for their safety and ability to intervene with HF progression.
Target groups
The content of this thesis is relevant for the scientific community, for future drug devel-
opment, and on the longer term for patients. Within the scientific community, increased 
understanding of the function of miRNAs during HF progression will benefit cardiac re-
searchers. In addition to the cardiac research field, basic research studying other disease 
etiologies may be aided by the content of this thesis. The cellular processes studied within 
this thesis are not restricted to be involved in cardiac disease progression only. Therefore, 
miRNAs described in this thesis to regulate these processes are most likely also involved 
in other disease settings. For example, manipulation of the miR-221/222 family may also 
impact hepatic or pulmonary fibrosis formation. Furthermore, inducing cell cycle arrest 
through induction of miR-125a may potentially affect tumor growth.
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Almost half of the HF patients will die within 5-years after diagnosis. This marks the 
ineffectiveness of current therapeutic strategies to treat HF patients. Therefore, new drugs 
should be developed to save the lives of millions of people globally. Although the end re-
sult by means of a successful clinically utilised therapy lies beyond the horizon, we as basic 
scientists should strive for expansion of the scientific body of knowledge to increase the 
chances of developing life-saving therapeutic approaches. Although this thesis highlights 
multiple miRNAs crucially involved in processes underlying failure of the heart, different 
challenges need to be overcome before miRNA-based strategies can undergo widespread 
implementation, as discussed in the discussion section.
Described novel knowledge on how miRNAs control the development of heart failure 
is only of indirect value to the current patient population. Further rigorous investigation of 
these miRNA candidates is necessary to determine safety and efficacy in patients. However, 
the findings in this thesis will advance our understanding of the involvement of miRNAs in 
cardiac disease. Ultimately, patients will benefit from developed miRNA-based therapies, 
alleviating the heavy burden of HF on society.
Innovation, products, and implementation
Current ineffective therapeutic strategies to treat HF patients are not aimed at targeting 
miRNAs. This thesis proves an altered expression profile and functional involvement of 
specific miRNAs in the failing heart. These findings mark an innovative treatment approach 
in which therapies are designed to modulate miRNA function to impact HF progression. 
MiRNA identified by us using in vitro high-throughput screening, or specific miRNAs tested 
in animal models may form the basis for drug development. However, the process of de-
veloping a clinically applicable therapeutic strategy based on basic research is a long and 
costly process, making it difficult to predict the long-term value of this thesis.
Independent of the future development of miRNA-based therapeutic approaches, 
communication of the content of the described research is crucial for future implementa-
tion. Findings of this thesis are communicated through multiple international scientific 
conferences in which we were invited to present our work. Moreover, we have submitted 
and published our scientific results to international peer-reviewed journals, allowing the 
scientific community and general public to get access to it.
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